You are using an outdated browser. Please upgrade your browser to improve your experience.
myHER2

The myHER2 app is an interactive and personalised support tool designed for women or men with HER2-positive breast cancer who have been prescribed Herceptin (trastuzumab) or Perjeta (pertuzumab) + Herceptin or Kadcyla (trastuzumab emtansine)

The myHER2 app is an interactive and personalised support tool designed for women or men with HER2-positive breast cancer who have been prescribed Herceptin (trastuzumab) or Perjeta (pertuzumab) + Herceptin or Kadcyla (trastuzumab emtansine)

myHER2

by Roche Products Pty Limited
myHER2
myHER2
myHER2

What is it about?

The myHER2 app is an interactive and personalised support tool designed for women or men with HER2-positive breast cancer who have been prescribed Herceptin (trastuzumab) or Perjeta (pertuzumab) + Herceptin or Kadcyla (trastuzumab emtansine).

myHER2

App Details

Version
1.5.1
Rating
(1)
Size
112Mb
Genre
Medical Health & Fitness
Last updated
October 22, 2020
Release date
November 17, 2016
More info

App Store Description

The myHER2 app is an interactive and personalised support tool designed for women or men with HER2-positive breast cancer who have been prescribed Herceptin (trastuzumab) or Perjeta (pertuzumab) + Herceptin or Kadcyla (trastuzumab emtansine).
The Home Screen displays the key modules of the app.
The app includes features such as:
• Treatment Plan - to assist in managing infusion appointments
• Symptom Tracker - to log symptoms and track well-being
• Support Resources - information about HER2-positive breast cancer, treatment and direct access to support networks
• Personal Profile - to store the healthcare and emergency contact details.

Disclaimer:
AppAdvice does not own this application and only provides images and links contained in the iTunes Search API, to help our users find the best apps to download. If you are the developer of this app and would like your information removed, please send a request to takedown@appadvice.com and your information will be removed.